Sponsors (7)
The bill trades stronger FDA oversight and broader legal remedies for clearer, product-specific rules and easier market access for homeopathic products—preserving consumer access and reducing industry uncertainty but raising risks to safety, enforcement, and potential public costs.
Consumers who use homeopathic products (including patients with chronic conditions) retain broader access to those products because the bill reduces federal premarket barriers and affirms their status under a statutory homeopathic pathway.
Manufacturers and sellers (including small businesses, hospitals, and state regulators) gain clearer, homeopathy-specific statutory definitions and reduced regulatory uncertainty—e.g., removal of the 2022 FDA guidance and clearer standards—making compliance and market entry more predictable.
Manufacturers face fewer specific FDA new-animal-drug hurdles and a more predictable petition process (including automatic approval after 180 days), which can lower costs and speed product changes or market entry.
Patients and other consumers face increased health and safety risk because the bill reduces FDA oversight and premarket testing/identity/strength requirements for many homeopathic products, potentially allowing ineffective or unsafe products to remain widely available.
Federal agencies and regulators may be constrained from imposing stricter safety or labeling standards and face higher procedural burdens (including shifted burdens of proof and de novo judicial review), making it harder to remove unsafe or misbranded homeopathic products from the market.
The bill limits legal remedies and oversight by preempting or restricting FTC/state substantiation actions and private lawsuits, reducing consumers' ability to challenge misleading efficacy claims or seek redress.
Based on analysis of 12 sections of legislative text.
Establishes a distinct federal regulatory pathway for homeopathic drug products with tailored standards, prohibits FDA premarket approval for them, and withdraws specified FDA guidance for covered products.
Official title: To amend the Federal Food, Drug, and Cosmetic Act with respect to homeopathic drug products, and for other purposes.
Introduced January 14, 2026 by Pete Sessions · Last progress January 14, 2026
Creates a new, separate federal regulatory pathway for homeopathic drug products that narrows the application of many FD&C Act requirements to those products, defines ‘‘homeopathic drug product’’ and related terms, and prevents the FDA from treating those products under existing guidance cited in 2022. It sets product and manufacturing standards tailored to homeopathy (including alternative GMPs), prohibits premarket approval for homeopathic products, requires registration/listing, establishes an advisory committee for homeopathic drugs, preserves state regulation of the practice of homeopathy, and provides judicial de novo review with the burden on the United States in enforcement actions. The bill also withdraws a specific FDA guidance as to covered homeopathic products and includes a severability clause.